<DOC>
	<DOCNO>NCT00101257</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , cellular adoptive immunotherapy , stimulate immune system different way stop tumor cell grow . PURPOSE : This phase I trial study side effect best dose cellular adoptive immunotherapy treat patient stage III stage IV ovarian cancer primary peritoneal cancer .</brief_summary>
	<brief_title>Cellular Adoptive Immunotherapy Treating Patients With Stage III Stage IV Ovarian Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety toxicity autologous CD4-positive antigen-specific T cell patient stage III IV ovarian epithelial cancer primary peritoneal cavity cancer . - Determine duration vivo persistence drug patient . Secondary - Determine antitumor effect drug patient . OUTLINE : This dose-escalation study . Patients undergo leukapheresis collection T cell . Responder T cell stimulate vitro autologous peripheral blood mononuclear cell-derived dendritic cell pulse NY-ESO-1 immunogenic peptide . Patients receive autologous CD4-positive antigen-specific T cell IV 30 minute . Cohorts 3-6 patient receive escalate dos autologous CD4-positive antigen-specific T cell maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 4 , 8 , 12 week periodically thereafter survival . PROJECTED ACCRUAL : A total 9-18 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV ovarian epithelial cancer primary peritoneal cavity cancer meet 1 follow criterion : Progressive* persistent* disease primary chemotherapy Recurrent disease &lt; 6 month completion primary therapy result complete response Persistent* recurrent disease secondline additional therapy NOTE : *Progression persistence base serological ( CA 125 &gt; 100 U/mL OR 2 time baseline ) , radiographic ( measurable evaluable disease ) , secondlook surgical finding Tumor express NYESO1 determine IHC RTPCR HLA type express DPB*0401 , DPB1*0201 , DRB1*07 No CNS metastases PATIENT CHARACTERISTICS : Age 18 75 Performance status Karnofsky 70100 % Life expectancy More 16 week Hematopoietic Not specify Hepatic Not specify Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No congestive heart failure* No clinically significant hypotension* No symptom coronary artery disease* No cardiac arrhythmia EKG require drug therapy* No history cardiovascular disease* No significant cardiovascular abnormalities* NOTE : *Patients undergo stress test and/or echocardiography determine ineligible study participation Pulmonary FEV_1 ≥ 60 % predicted* DLCO ≥ 55 % * NOTE : *Patients clinically significant pulmonary dysfunction Other Not pregnant nursing Fertile patient must use effective contraception HIV negative No active infection No oral temperature &gt; 38.2°C within past 72 hour No systemic infection require chronic maintenance suppressive therapy PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy ( e.g. , interleukin , interferon , vaccine , intravenous immunoglobulin , expand polyclonal tumorinfiltrating lymphocyte lymphokineactivated killer cell therapy ) Chemotherapy See Disease Characteristics At least 3 week since prior standard experimental chemotherapy Endocrine therapy No concurrent systemic corticosteroid except treatmentrelated toxicity Radiotherapy At least 3 week since prior radiotherapy Surgery See Disease Characteristics Other At least 3 week since prior immunosuppressive therapy More 3 week since prior investigational drug recover No concurrent investigational agent No concurrent pentoxifylline</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>